COVID19 is relevant to Amarins story in the following way
1) As we increasingly self isolate ....non urgent MD visits will be postponed 2) Sales reps who have kids in school ( mothers and / or single parents ) will scramble to find some one to take care of their children ...or stay at home themselves ..as schools are closed . All the schools in my town will be closed starting Monday for 3 weeks. 3) ACC20 was cancelled and is now probably going virtual . This was a major marketing event for Amarin ...which will likely now be less effective . 4) The script number jump you cited is largely pre ordering IMHO. I pre ordered all my mail order meds ( except Vascepa as I had just received a 90 day supply ) 5) Peoples attention for the next several weeks is likely to be focused on how to avoid contacting COVID19 ...not on some new drug out there that lowers CV event risk
All of these negative forces are coming at a time as Amarins marketing cost ramp up . These marketing costs are for the moment fixed costs
Vascepa is a great drug and IMHO will eventually be used by millions . If you believe the Co will win the patent battle then these current prices are a very attractive purchasing point ....and I have been adding.
But to think that the spread of COVID19 and its affect on our society ...... is not relevant to AMRN ....will not affect Amarins ability to market Vascepa.... is IMHO plain wrong .